https://oblatoinc.com/recruitment/https://oblatoinc.com/clinical-trials/https://oblatoinc.com/clinical/https://oblatoinc.com/contact-us/https://oblatoinc.com/media/https://oblatoinc.com/patients/https://oblatoinc.com/pipeline/https://oblatoinc.com/our-science/https://oblatoinc.com/about-oblato/https://oblatoinc.com/https://oblatoinc.com/2023/07/28/oblato-announces-the-first-enrollment-in-a-phase-1-clinical-trial-for-an-oral-formulation-of-okn-007-in-recurrent-high-grade-glioma-patients-in-the-usa/https://oblatoinc.com/2022/11/01/oblato-announces-that-it-has-completed-enrollment-of-patients-for-the-phase-2-recurrent-glioblastoma-multiforme-clinical-trial-in-the-us/https://oblatoinc.com/2021/07/21/oblato-announces-that-it-has-received-a-positive-response-from-the-fda-for-the-use-of-okn-007-for-patients-with-high-grade-gliomas-in-an-expanded-access-program/https://oblatoinc.com/2021/03/05/oblato-announces-fast-track-designation-of-okn-007-for-diffuse-intrinsic-pontine-glioma-from-the-fda/https://oblatoinc.com/2021/03/02/oblato-announces-discussion-outcome-with-fda-for-development-of-okn-007-for-diffuse-intrinsic-pontine-glioma/https://oblatoinc.com/2021/03/02/brain-cancer-survivor-marks-thanksgiving-milestone/https://oblatoinc.com/2021/03/02/brain-tumor-drug-receives-rare-disease-designations-from-the-fda/https://oblatoinc.com/category/news/https://oblatoinc.com/author/oblato/https://oblatoinc.com/author/specialog/